Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-23T22:55:36.208Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug-induced psychosis in Parkinson's disease (II): atypicalneuroleptics

Published online by Cambridge University Press:  18 September 2015

E.CH. Wolters ,
G. Tissingh ,
M.A. Kuiper ,
W.A. Zwaan  and
M.W.I.M. Horstink
E.CH. Wolters*
Affiliation:
Afdeling Neurologie, Academisch Ziekenhuis der Vrije Universiteit
G. Tissingh
Affiliation:
Afdeling Neurologie, Academisch Ziekenhuis der Vrije Universiteit
M.A. Kuiper
Affiliation:
Afdeling Neurologie, Academisch Ziekenhuis der Vrije Universiteit
W.A. Zwaan
Affiliation:
Afdeling Psychiatrie, Academisch Ziekenhuis der Vrije Universiteit
M.W.I.M. Horstink
Affiliation:
Afdeling neurologie, Academisch Ziekenhuis Nijmegen.
*
Postbus 7057, 1007 MB Amsterdam, Tel. 020-5482818
Get access Rights & Permissions [Opens in a new window]

Summary

In this second part of a review on drug-induced psychosis in Parkinson's disease, the characteristics of typical and atypical neuroleptics will be compared and the therapeutic efficacy and the extrapyramidal side-effects of ‘atypical’ antipsychotic drugs will be discussed. These drugs affect serotonergic, adrenergic as well as dopaminergic neurotransmission and are best distinguished from the typical neuroleptics on the basis of the relationship between strong 5-HT2 and weak D2 affinities. Their succes may rely on this spectrum of effects. Clozapine, being the first choice, will be discussed in more detail.

Keywords

Parkinson's diseasedopaminepsychosisatypische neurolepticaclozapineziekte van Parkinsondopaminepsychoseatypische neurolepticaclozapine
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 6 , Issue 3 , September 1994 , pp. 43 - 47
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Stoof, JC, Booij, J, Drukarch, B, Wolters, ECh.The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic-acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Europ J Pharmacol 1992;231:439–43.CrossRefGoogle Scholar
2.Casey, DE.Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991;4:109–20.CrossRefGoogle ScholarPubMed
3.Coward, DM, Imperato, A, Urwyler, S, White, TG.Biochemical and behavioural properties of clozapine. Psychopharmacol (Berl) 1989;99:S6–12.CrossRefGoogle ScholarPubMed
4.Janssen, PAJ.The pharmacology of neuroleptic drugs. In: Haase, HJ, Janssen, PAJ. eds. The action of neuroleptic drugs. Amsterdam: Elsevier, publ. 1985:285–317.Google Scholar
5.Ellenbroek, BA, Artz, MT, Cools, AR.The involvement of dopamine D1, and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Europ J Pharmacol 1991;196:103–8.CrossRefGoogle ScholarPubMed
6.Van Tol, HH, Bunzow, JR, Guan, HC, et al.Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610–4.CrossRefGoogle ScholarPubMed
7.Gerlach, J, Hansen, L.Clozapine and D1/D2 antagonism in extrapyramidal functions. Br J Psychiat 1992;160(S17):34–7.CrossRefGoogle Scholar
8.Farde, L, Nordstrom, AL, Wiesel, FA, Pauli, S, Halldin, C, Sedvall, G.Positron emission tomography analysis of striatal D1, and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiat 1992;49:538–44.CrossRefGoogle Scholar
9.Pilowsky, LS, Costa, DC, Ell, PJ, Murray, RM, NPLG, Verhoeff, Kerwin, RW.Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992;340:199–202.CrossRefGoogle ScholarPubMed
10.Meltzer, HY, Matsubara, S, Lee, JC.Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pKi-values. J Pharmacol exp Ther 1989;251:238–46.Google ScholarPubMed
11.Wadenberg, ML, Ahlenius, S, Svensson, TH.Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine. Psychopharmacol 1993;110:273–9.CrossRefGoogle ScholarPubMed
12.Nördstrom, AL, Farde, L, Halldin, C.High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacol 1993;110:365–7.CrossRefGoogle ScholarPubMed
13.Meltzer, HY, Stockmeier, GA.In vivo occupancy of dopamine receptors by antipsychotic drugs. Arch Gen Psychiat 1992;49:588–9.CrossRefGoogle ScholarPubMed
14.Arnt, J.Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol toxicol (Copenh) 1982;51:321–9.CrossRefGoogle ScholarPubMed
15.Moore, NA, Tye, NC, Axton, MS, Risius, FC.The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther 1992;262:545–51.Google ScholarPubMed
16.Meltzer, HY, Nash, JF.The effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991;43:587–604.Google ScholarPubMed
17.Bersani, G, Grispini, A, Marini, S.Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R35667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 1986;40:492–9.Google Scholar
18.Jansen, EN, Rolling, P.Letter to the editor. Ned Tijdschr Geneeskd; 136:755–6.Google Scholar
19.Touw, DJ, Gernaat, HBPE, van de Woude, J.Parkinsonisme na toevoeging van fluoxetine aan behandeling met neuroleptica of carbamazepine. Ned Tijdschr Geneeskunde 1992;136:332–4.Google ScholarPubMed
20.Claus, A, Bollen, J, De Cuyper, H, Eneman, M, Malfroid, M, Peuskens, J, Heylen, S.Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a multicenter double-blind comparative study. Acta psychiat scand 1992;85:295–305.CrossRefGoogle Scholar
21.Pickar, D, Owen, RR, Litman, RE, Konicki, E, Gutierrez, R, Rappaport, MH.Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiat 1992;49:345–53.CrossRefGoogle ScholarPubMed
22.Tandon, R, Greden, JF.Cholinergic hyperactivity and negative schizophrenic symptoms: a model of cholinergic interactions in schizophrenia. Arch Gen Psychiat 1989;46:745–53.CrossRefGoogle Scholar
23.Fischer, PA, Baas, H, Hefner, R.Treatment of parkinsonian tremor with clozapine. J neural Transm [Park Dis Dement Sect] 1990;2:233–8.CrossRefGoogle ScholarPubMed
24.Rivest, R, Marsden, CA.Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not haloperidol. Br J Pharmacol 1991;104:234–8.CrossRefGoogle Scholar
25.Schwartz, JT, Brotman, AW.A clinical guide to antipsychotic drugs. Drugs 1992;44:981–92.CrossRefGoogle ScholarPubMed
26.Greene, P, Cote, L, Fahn, S.Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993;60:703–6.Google ScholarPubMed
27.Kahn, N, Freeman, A, Juncos, JL, Manning, D, Watts, RL.Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991;41:1699–1700.CrossRefGoogle ScholarPubMed
28.Wolters, ECh, Hurwitz, TA, Mak, E, et al.Clozapine in the treatment of parkinsonian patients with dopaminemimetic psychosis. Neurology 1990;40:832–4.CrossRefGoogle Scholar
29.Friedman, JH, Lannon, MC.Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989;39:1219–21.CrossRefGoogle ScholarPubMed
30.Pfeiffer, RF, Kang, J, Graber, B, Hofman, R, Wilson, J.Clozapine for psychosis in Parkinson's disease. Mov Disord 1990;5:239–42.CrossRefGoogle ScholarPubMed
31.Wolters, ECh, Hurwitz, TA, Peppard, RF, Calne, DB.Clozapine: an antipsychotic agent in Parkinson's disease. Clin Neuropharmacol 1989;12:83–90.CrossRefGoogle ScholarPubMed
32.Ostergard, K, Dupont, E.Clozapine treatment of drug-induced psychotic symptoms in the late stages of Parkinson's disease. Acta neurol scand 1988;78:349–50.CrossRefGoogle Scholar
33.Factor, SA, Brown, D.Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992;7:125–31.CrossRefGoogle ScholarPubMed
34.Pinter, MM, Helscher, RJ.Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J neural Transm [Park Dis Dement Sect] 1993;5:135–46.CrossRefGoogle ScholarPubMed
35.Scholz, E, Dichgans, J.Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiat neurol Sci 1985;235:60–4.CrossRefGoogle ScholarPubMed
36.Lew, MF, Waters, CH.Clozapine treatment of parkinsonism with psychosis. JAGS 1993;41:669–71.CrossRefGoogle ScholarPubMed
37.Szymanski, S, Jody, D, Leipzig, R, Masiar, S, Lieberman, J.Anticholinergic delirium caused by retreatment with clozapine. Am J Psychiat 1991;148:1752.Google ScholarPubMed
38.Devinski, O, Honigfeld, G, Patin, J.Clozapine-related seizures. Neurology 1991;41:369–71.CrossRefGoogle Scholar
39.Liukkonen, J, Koponen, HJ, Nousiainen. Clinical picture and longterm course of epileptic seizures that occur during clozapine treatment. Psychiatry Res 1992;44:107–12.CrossRefGoogle ScholarPubMed
40.Rosen, SI, Hanno, PM.Clozapine-induced priapism. J Urol 1992;148:876–7.CrossRefGoogle ScholarPubMed
41.Ogilvie, AD, Croy, MF.Clozapine and hyponatraemia. Lancet 1992;II:672.CrossRefGoogle Scholar
42.Stoppe, G, Muller, P, Fuchs, T, Riither, E.Life-threatening allergic reaction to clozapine. Br J Psychiat 1992;161:259–61.CrossRefGoogle ScholarPubMed
43.Launer, M.Diarrhoea during treatment with clozapine. Br Med J 1992;305:1160.CrossRefGoogle ScholarPubMed
44.Tiihonen, J, Paanila, J.Eosinophilia associated with clozapine. Lancet 1992;i:488.CrossRefGoogle Scholar
45.Cohen, S, Chiles, J, MacNaughton, A.Weight gain associated with clozapine. Am J Psychiat 1990;147:503–4.Google ScholarPubMed
46.Daly, JM, Goldberg, RJ, Braman, SS.Polyserositis associated with clozapine treatment. Am J Psychiat 1992;149:1274–5.Google ScholarPubMed
47.Krupp, P, Barnes, P.Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiat 1992;160:38–40.CrossRefGoogle Scholar
48.Lieberman, JA, Alvir, JM.A report of clozapine-induced agranulocytosis in the United states. Incidence and risk factors. Drug Saf 1992;7(S1):1–2.CrossRefGoogle ScholarPubMed
49.Joseph, G, Smith, JD.HLA-B38 and clozapine-induced agranulocytosis. Ann intern Med 1992; 116:605.CrossRefGoogle ScholarPubMed
50.Zoldan, J, Friedberg, G, Goldberg-Stern, H, Melamed, E.Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993;341:562–3.CrossRefGoogle ScholarPubMed
51.Lapierre, TD, Nair, NPV, Chouinard, Get al.A controlled doseranging study of remoxipride and haloperidol - A Canadian multicentre trial. Acta psychiat scand 1990;82(S358):72–6.CrossRefGoogle Scholar
52.Lewander, T, Westerbergh, SE, Morrison, D.Clinical profile of remoxipride-a combined analysis of a comparative double-blind multicentre trial programme. Acta psychiat scand 1990;82(S358):92–8.CrossRefGoogle Scholar
53.Muller-Spahn, F.Risperidone in the treatment of chronic schizophrenic patients. Clin Neuropharmacol 1992;15(S1):90–1.CrossRefGoogle ScholarPubMed
54.Hillert, A, Maier, W, Wetzel, H, Benkert, O.Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome: a functional approach. Pharmacopsychiatry 1992;263:350–9.Google Scholar
55.Gross, G, Xin, X, Gastpar, M.Trimipramine: pharmacological reevaluation and comparison with clozapine. Neuropharmacol 1991;30:1159–66.CrossRefGoogle ScholarPubMed